Benefits of long-term routine lab drug toxicity monitoring unclear in rheumatoid arthritis

For patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs), long-term routine laboratory toxicity monitoring (lt-RLTM) indicates that most very abnormal laboratory results are already known or suspected, according to a study published online Aug. 26 in the Annals of Internal Medicine.